Shire's angioedema drug succeeds in late-stage study

May 18 (Reuters) - Shire Plc said on Thursday its drug for hereditary angioedema (HAE), a disorder characterized by recurrent episodes of severe swelling, was successful in a late-stage study.

The drug, lanadelumab, is being developed to prevent angioedema attacks. It was tested against a placebo over 26 weeks in patients 12 years of age or older with the rare genetic disease. (Reporting by Natalie Grover in Bengaluru; Editing by Martina D'Couto)